Does Testosterone Replacement Therapy Cause Prostate Enlargement?
Testosterone replacement therapy (TRT) does cause a modest increase in prostate volume, but this growth is clinically minor and typically brings the prostate to normal size ranges comparable to age-matched eugonadal men. The evidence consistently shows that while TRT increases prostate volume, it does not significantly worsen urinary symptoms or substantially increase prostate-specific antigen (PSA) levels beyond expected physiological ranges 1.
Understanding the Prostate Growth Pattern
Magnitude of Growth
The prostate enlargement associated with TRT is modest and predictable:
- Average PSA increase: 0.3 ng/mL in young hypogonadal men and 0.44 ng/mL in older men 1
- Recent longitudinal data: TRT increases prostate growth rate by only 0.22 mL/year compared to untreated periods 2
- Normalization effect: Untreated hypogonadal men have significantly smaller prostates (mean 12.2 mL) compared to both testosterone-treated men (21.3 mL) and normal eugonadal men (22.9 mL), indicating TRT restores prostate size to physiologically normal ranges rather than causing pathological enlargement 3
Clinical Impact on Urinary Function
Critically, prostate volume increases from TRT do not translate into worsening urinary symptoms. The most recent longitudinal study found no significant differences in lower urinary tract symptoms (LUTS), quality of life, or urinary flow rates between treated and untreated periods despite the small increase in prostate growth 2. This finding is corroborated by earlier controlled studies showing no differences in uroflow parameters between testosterone-treated hypogonadal men and normal controls 3.
Monitoring Requirements Per Guidelines
The 2018 Endocrine Society guidelines provide specific thresholds for monitoring 1:
Baseline evaluation:
- Digital rectal examination (DRE)
- PSA measurement
- Voiding history or standardized questionnaire
- Prostate biopsy if PSA >4.0 ng/mL or abnormal DRE
Follow-up monitoring:
- Check PSA and perform DRE at 3-12 months after initiating TRT
- Then follow age-appropriate prostate cancer screening guidelines
- Measure hematocrit at baseline, 3-6 months, then annually
Triggers for urological referral:
- PSA increase >1.4 ng/mL within 12 months of starting TRT 1
- Confirmed PSA >4.0 ng/mL at any time
- Detection of prostatic abnormality on DRE
- Substantial worsening of LUTS
Important Clinical Nuances
The PSA Increase Is Expected, Not Alarming
The guidelines emphasize that PSA elevations >1.4 ng/mL during 3-6 months after TRT are unusual (occurring in only 2.4% at 3 months and 4.7% at 12 months in the TTrials) 1. The 90% confidence limit for PSA change is 1.4 ng/mL, making this the appropriate threshold for concern rather than any PSA rise 1.
Tissue-Level Effects Are Minimal
A critical randomized controlled trial found that while TRT normalized serum testosterone levels, it had no significant effect on prostate tissue androgen levels (testosterone or dihydrotestosterone), prostate histology, tissue biomarkers, or gene expression after 6 months 4. This suggests the modest volume increase occurs without substantial cellular proliferation or pathological changes.
Genetic Factors Matter
The androgen receptor CAG repeat polymorphism significantly influences prostate growth during TRT. Men with shorter CAG repeats (<20) have an odds ratio of 8.7 for developing prostate size ≥30 mL compared to those with longer repeats, particularly in men over 40 years 5. However, this genetic variation doesn't change the overall safety profile—it simply identifies men who may experience more growth within the normal physiological range.
Common Pitfalls to Avoid
Don't confuse PSA monitoring with causation: The increased detection of prostate cancer during TRT is primarily due to enhanced surveillance and PSA-triggered biopsies, not necessarily TRT causing cancer 1
Confirm PSA elevations before acting: Transient PSA elevations are common due to test-retest variability, prostatitis, benign prostatic hyperplasia, or urinary tract infections 1. Always repeat elevated PSA before referring for biopsy.
Recognize the saturation model: The evidence suggests prostate tissue androgen levels reach saturation at relatively low serum testosterone concentrations, explaining why normalizing serum testosterone doesn't proportionally increase prostate tissue androgens 4
Engage in shared decision-making: Given the controversy over prostate cancer screening, discuss risks and benefits with patients before initiating TRT, particularly for men 55-69 years old 1
Bottom Line for Clinical Practice
TRT causes a small, predictable increase in prostate volume that normalizes the gland to sizes comparable with eugonadal men. This growth does not worsen urinary symptoms or substantially increase cancer risk when appropriate monitoring is followed. The key is adhering to guideline-based PSA and DRE surveillance with clear thresholds for urological referral, while avoiding unnecessary biopsies triggered by expected physiological PSA increases.